[1]陈 津,彭 伟,崔兆磊,等.食管癌放疗患者血清涎液化糖链抗原水平检测在预测放射性肺炎的风险评估[J].现代检验医学杂志,2020,35(03):126-128.[doi:10.3969/j.issn.1671-7414.2020.03.034]
 CHEN Jin,PENG Wei,CUI Zhao-lei,et al.Serum KL-6 Predicts the Risk of Pneumonitis Induction after Radiotherapy of Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2020,35(03):126-128.[doi:10.3969/j.issn.1671-7414.2020.03.034]
点击复制

食管癌放疗患者血清涎液化糖链抗原水平检测在预测放射性肺炎的风险评估()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年03期
页码:
126-128
栏目:
检验与临床
出版日期:
2020-07-20

文章信息/Info

Title:
Serum KL-6 Predicts the Risk of Pneumonitis Induction after Radiotherapy of Esophageal Cancer
文章编号:
1671-7414(2020)03-126-04
作者:
陈 津彭 伟崔兆磊陈 燕
(福建省肿瘤医院/ 福建医科大学附属肿瘤医院检验科,福州 350014)
Author(s):
CHEN Jin PENG Wei CUI Zhao-lei CHEN Yan
(Department of Clinical Laboratory, Fujian Cancer Hospital/ Affiliated Cancer Hospital,Fujian Medical University, Fuzhou 350014,China)
关键词:
食管癌放射性肺炎涎液化糖链抗原 风险评估工作特征曲线
分类号:
R735.1;R730.43 
DOI:
10.3969/j.issn.1671-7414.2020.03.034
摘要:
目的 探讨食管癌患者在放疗前后血清中涎液化糖链抗原(krebs von den Lungen-6,KL-6)水平的变化在预警 放射性肺炎(radiation pneumonitis,RP)发生的价值。方法 对39 例在2017 年7 ~ 12 月期间接受放射治疗的食管癌患 者进行随访,留取放疗开始前及放疗开始后的1,2,3,4 个月内的血清,将其分为RP 组(9 例)和非RP 组(30 例), 采用电化学发光法(ECLI)检测两组患者血清中KL-6 水平的变化。结果 放疗前,RP 组和非RP 组的血清KL-6 水平 差异无统计学意义(t=1.480,P=0.147), 而从放疗开始后的1~4 个月,RP 组的血清KL-6 水平显著高于非RP 组,差异 有统计学意义(t=6.977,P=0.001 和t=0.530,P=0.602), 对放疗前后KL-6 水平增高比值进行工作特征曲线(ROC)分析, 结果显示最佳诊断界限为1.4,灵敏度,特异度和AUC 分别为66.7%,96.7%,0.934。结论 血清KL-6 水平在监测食 管癌患者发生RP 方面有重要意义, 当食管癌病人接受放疗后血清KL-6 水平升高且与放疗前水平之比大于1.4 时,提示 该患者罹患RP 的可能性较大。
Abstract:
Objective To study the serum levels of KL-6 in predicting radiation pneumonia (RP) before and after radiotherapy.Methods A total of 39 hospitalized patients with esophageal cancer were followed up between July to December in 2017. To collect the serum of 39 patients before and after the treatment in 1, 2, 3 and 4 months. The patients were divided into the RP group (9 cases) and non-RP group (30 cases). The levels of KL-6 changes in the two groups were detected by electrochemiluminescence immunoassay (ECLI). Results Before radiotherapy, there was no significant difference (t=1.480, P=0.1471)in serum KL-6 between RP group and non RP group. From 1~4months after radiotherapy, the serum KL-6 levels in RP group was significanty higher than that in non RP group (t=6.977,P=0.001,t=0.530,P=0.602). ROC analysis showed that the best diagnostic limit was 1.4 and the sensitivity, specificity and AUC were 66.7%,96.7% and 0.934 respectively. Conclusion  The levels of serum KL-6 is of great clinical significance in monitoring RP of esophageal cancer patients, that is, when the levels of serum KL-6 increases after radiotherapy and the ratio of KL-6 to the levels before radiotherapy was greater than 1.4, it indicates that the patients are more likely to have RP.

参考文献/References:

[1] 王军, 肖林林, 程云杰. 局部进展期食管癌新辅助治 疗研究进展 [J]. 中华放射肿瘤学杂志,2018,27(8):709- 720.    WANG Jun, XIAO Linlin, CHENG Yunjie. Research progress in neoadjuvant treatment of locally advanced esophageal cancer[J].Chinese Journal of Radiation of Oncology, 2018,27(8):709-720.
[2] 鲍艳红,黄常新. 放射性肺炎的发病机制及其防治 研究进展[J]. 实用医学杂志,2015,31(21):3621- 3623.    BAO Yanhong , HUANG Changxin. Research progress in the pathogenesis and prevention of radiation pneumonia[J].The Journal of Practical Medicine, 2015,31(21):3621-3623.
[3] 何佳欣,朱小辉,鞠永健.KL-6 与放射性肺炎的相 关研究进展[J]. 癌症进展,2014,12(3):242-245.    HE Jiaxin, ZHU Xiaohui, JU Yongjian. Research progress of KL-6 and radiation pneumonia [J]. Oncology Progress, 2014,12(3): 242-245.
[4] 李波,赵永利,李开艳,等.放疗致肺癌患者发生 放射性肺炎的影响因素研究[J].中国全科医学, 2015, 18(14): 1659-1662.    LI Bo, ZHAO Yongli, LI Kaiyan, et al. Influencing factors for radiation pneumonitis induced by radiation therapy for lung cancer [J]. Chinese General Practice, 2015,18(14):1659-1662.
[5] SATO H, CALLISTER M E, MUMBY S, et al. KL-6 levels are elevated in plasma form patients with acute respiratory distress syndrome [J]. Eur Respir J, 2004,23 (1) : 142-145.
[6] MIYAZAKI K, KURISHIMA K, KAGOHASHI K, et al. Serum KL-6 levels in lung cancer patients with or without interstitial lung disease [J]. J Clin Lab Anal, 2010,24(5) ∶ 295-299.
[7]  SAKAMOTO K, TANIGUCHI H, KONDOH Y, et al. Serum KL-6 in fibrotic NSIP: Correlations with physiologic and radiologic parameter[J]. Respir Med,2010, 104 (1): 127-133.
[8]  ICHIYASU H, ICHIKADO K, YAMASHITA A, et al .Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in nonspecific interstitial pneumonia [J].Respiration, 2012, 83 (3): 190-197.
[9]  王冉冉,朱剑,张江林. KL-6 在间质性肺疾病诊治 中的研究进展[J]. 解放军医学杂志,2017,42(4): 354-357.    WANG Ranran, ZHU Jian, ZHANG Jianglin. Advances in the research on application of KL-6 in the diagnosis and treatment of interstitial lung disease[J].Medical Journal of Chinese people’s Liberation Army, 2017,42 (4):354-357.
[10] 温翠侠, 孙凌飞, 吴承俊, 等. 食管癌单纯放疗及同 期放化疗患者急性不良反应影响因素[J]. 北华大学 学报( 自然科学版),2019, 20(1):77-81.    WENG Cuixia, SUN Lingfei, WU Chengjun. Impact of radiotherapy and cxoncurrent chemoradiotherapy on acute adverse reactions in patients with esophageal cancer[J]. Journal of Beihua University(Natural Science), 2019, 20(1):77-81.
[11] 张鹏,王永才,张喜报,等 . 血清降钙素原、炎症 细胞因子及超敏 C- 反应蛋白联合检测放射性肺炎 合并肺部感染的诊断价值 [J]. 中华医院感染学杂 志,2017,27(23):5322-5324, 5347.    ZHANG Peng, WANG Yongcai, ZHANG Xibao, et al. Diagnostic value of serum calcitonin, inflammatory cytokines and high sensitivity C-reactive protein in the diagnosis of radiation pneumonia complicated with pulmonary infections[J]. Chinese Journal of Nosocomiology, 2017,27(23):5322-5324, 5347.
[12] GOTO K, KODAMA T, SEKINE I, et al. Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis[J].Lung Cancer, 2001, 34(1):141-148.
[13] MIYAZAKI Y, TSUTSUI T, INASE N.Treatment and Monitoring of hypersensitivity pneumonitis[J].Expert Rev Clin Immunol,2016,12(9):953-962.
[14] WASEDA K, OCHO K, HASEGAWA K, et a1.Increased serum KL-6 levels induced by pulmonary mycobactefium avium complex infection in a patient with RA-associated lung disease[J].Acta Med Okayama, 2016, 70(3):217-221.
[15] SUWABE A.Lung injury and serum markers[J]. Rinsho Byori, 2002,50(11):1061-1066.
[16] 蒋娟,胡成平. 放射性肺炎发病机制及治疗进展[J]. 国际呼吸杂志,2015,35(18):1427-1430.    JIANG Juan, HU Chengping. Advances in pathogenesis and treatment of radiation pneumonitis[J].International Journal of Respiration, 2015, 35(18): 1427-1430.

相似文献/References:

[1]张 振,李 力,徐翠香,等.血清TAM和Cyfra21-1检测在食管癌诊断和化疗疗效判定中的价值[J].现代检验医学杂志,2015,30(04):150.[doi:10.3969/j.issn.1671-7414.2015.04.046]
 ZHANG Zhen,LI Li,X(¨overU)Cui-xiang,et al.Value of Detecting Serum TAM and Cyfra21-1 Levels in the Diagnosis and Chemotherapeutic Efficacy of Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2015,30(03):150.[doi:10.3969/j.issn.1671-7414.2015.04.046]
[2]朱卫华,刘继斌.血浆相关基因甲基化在食管癌复发中的临床价值[J].现代检验医学杂志,2016,31(04):93.[doi:10.3969/j.issn.16717-414.2016.04.025]
 ZHU Wei-hua,LIU Ji-bin.Clinical Significance of Promoter Hypermethylation of Esophageal Squamous Cell Carcinoma(ESCC)in Plasma[J].Journal of Modern Laboratory Medicine,2016,31(03):93.[doi:10.3969/j.issn.16717-414.2016.04.025]
[3]肖小平,张 熊sub>a,秦光明b.食管癌和良性食管疾病患者血浆miRNA-21和miRNA-143检测的临床应用研究[J].现代检验医学杂志,2017,32(04):72.[doi:10.3969/j.issn.1671-7414.2017.04.020]
 XIAO Xiao-ping,ZHANG Xionga,QIN Guang-mingb.Clinical Research of Detecting Plasma MiRNA-21 and MiRNA-143 for Identifying Early Esophageal Cancer and Benign Esophageal Diseases[J].Journal of Modern Laboratory Medicine,2017,32(03):72.[doi:10.3969/j.issn.1671-7414.2017.04.020]
[4]邱 巍,胡 威,赵建江,等.江苏宿迁地区汉族人群DNMT3B基因启动子区-149C>T和-579G>T多态性与食管癌易感性的分析[J].现代检验医学杂志,2018,33(02):28.[doi:10.3969/j.issn.1671-7414.2018.02.001]
 QIU Wei,HU Wei,ZHAO Jian-jiang,et al.Study on the Promoter Region -149C>T and -579G>T Polymorphism of DNMT3B with Genetic Susceptibility to Esophageal Cancer of Han Population in Jiangsu Suqian[J].Journal of Modern Laboratory Medicine,2018,33(03):28.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[5]梁晓虎,郭俊霞,雷尚昆.食管癌组织中lnc RNA DNAJC3-AS1的表达及其与临床病理特征的相关性研究[J].现代检验医学杂志,2021,36(02):75.[doi:doi:10.3969/j.issn.1671-7414.2021.02.018]
 LIANG Xiao-hu,GUO Jun-xia,LEI Shangkun.Expression of Lnc RNA DNAJC3-AS1 in Esophageal Carcinoma Tissues and Its Correlation with Clinicopathological Features[J].Journal of Modern Laboratory Medicine,2021,36(03):75.[doi:doi:10.3969/j.issn.1671-7414.2021.02.018]
[6]朱 娇a,孙国才b,刘素荣a,等.食管癌患者血清神经元特异性烯醇化酶与长链非编码RNA ITGA9-AS1水平联合检测的实验诊断价值研究[J].现代检验医学杂志,2021,36(05):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
 ZHU Jiaoa,SUN Guo-caib,LIU Su-ronga,et al.Experimental Diagnostic Value of Combined Detection of SerumNeuron-Specific Enolase and Long Non-Coding RNA ITGA9-AS1 inPatients with Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2021,36(03):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
[7]贾东辉,杜 宇,黄 飞,等.食管癌患者行根治性切除术后血清miR-216a和Bcl-2mRNA表达水平及与预后的相关性研究[J].现代检验医学杂志,2022,37(02):93.[doi:10.3969/j.issn.1671-7414.2022.02.020]
 JIA Dong-hui,DU Yu,HUANG Fei,et al.Expression Levels of Serum miR-216a and Bcl-2 mRNA and Their Correlation with Prognosis in Patients with Esophageal Cancer after Radical Resection[J].Journal of Modern Laboratory Medicine,2022,37(03):93.[doi:10.3969/j.issn.1671-7414.2022.02.020]
[8]刘 伟a,周 杨a,边 超a,等.miR-495 对食管癌细胞株Eca109 在不同放射剂量和顺铂浓度作用的影响及机制研究[J].现代检验医学杂志,2022,37(04):13.[doi:10.3969/j.issn.1671-7414.2022.04.003]
 LIU Weia,ZHOU Yanga,BIAN Chaoa,et al.Effect of miR-495 on Esophageal Cancer Cell Line Eca109 at Different Radiation Doses and Cisplatin Concentrations and Its Mechanism[J].Journal of Modern Laboratory Medicine,2022,37(03):13.[doi:10.3969/j.issn.1671-7414.2022.04.003]
[9]周立远,叶玉祥,林 琳,等.LncRNA CCAT1 调节miR-155 表达增强CD8+T 细胞对食管癌抗肿瘤活性的机制研究[J].现代检验医学杂志,2023,38(03):79.[doi:10.3969/j.issn.1671-7414.2023.03.014]
 ZHOU Li-yuan,YE Yu-xiang,LIN Lin,et al.Mechanism of LncRNA CCAT1 Regulating miR-155 Expression and Enhancing Anti-tumor Activity of CD8+T Cells Against Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2023,38(03):79.[doi:10.3969/j.issn.1671-7414.2023.03.014]

备注/Memo

备注/Memo:
收稿日期:2019-12-26 修回日期:2020-02-22作者简介:陈津(1981-),女,本科,主管检验师,研究方向:免疫学,E-mail:2298191807@qq.com。 通信作者:陈燕,Email:yanc99@sina.com。
更新日期/Last Update: 2020-07-20